Stay updated on GD2-SADA:177Lu-DOTA in GD2 Expressing Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the GD2-SADA:177Lu-DOTA in GD2 Expressing Solid Tumors Clinical Trial page.

Latest updates to the GD2-SADA:177Lu-DOTA in GD2 Expressing Solid Tumors Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision history updated: added v3.3.4 and removed v3.3.3; this appears to be a minor versioning update with no impact on study content or page functionality.SummaryDifference0.1%

- Check16 days agoChange DetectedThe screenshots indicate layout and styling updates to the Study Details page without altering core study content like eligibility criteria or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check23 days agoChange DetectedNo significant changes detected in the Study Details page; content and core data appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check31 days agoChange Detected- Added Locations: Arizona, California, Illinois, Michigan, New York, Ohio, Pennsylvania, Wisconsin; removed HHS Vulnerability Disclosure; Revision: v3.3.3.SummaryDifference1.0%

- Check45 days agoChange DetectedNo significant changes detected between the old and new screenshots of the Study Details page for NCT05130255.SummaryDifference0.1%

- Check59 days agoChange DetectedThe page revision was updated from v3.2.0 to v3.3.2. No substantive changes to trial details, eligibility criteria, contacts, or results are evident; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to GD2-SADA:177Lu-DOTA in GD2 Expressing Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GD2-SADA:177Lu-DOTA in GD2 Expressing Solid Tumors Clinical Trial page.